特發性肺纖維化（IPF）：新型療法、未滿足的需求和TPP洞察報告，2026年

市場概覽

• 德國市場預計將從約 2.1 億美元成長到約 4.15 億美元（年複合成長率約 7%）。
• 雖然抗纖維化療法和診斷技術的進步推動了經濟成長，但對根治性治療方法的需求仍然沒有得到滿足。

對特發性肺纖維化（IPF）新型治療方法和治療策略的深入了解

Thelansis 發布的《特發性肺纖維化 (IPF)：新興治療方法報告，包括未滿足的需求和 TPP 見解 - 2026》對該適應症的關鍵新興治療方法和主要藥物發現機會進行了全面分析，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、試驗設計和關鍵意見領袖 (KOL) 的見解。

特發性肺纖維化（IPF）概述

特發性肺纖維化（IPF）是一種病因不明的慢性進行性間質性肺部疾病，其特徵是肺實質不可逆性纖維化，高解析度CT和組織病理學檢查顯示典型的間質性肺炎（UIP）模式。此病主要影響60歲以上的成年人，是特發性間質性肺炎中最嚴重的類型之一。

臨床上，特發性肺纖維化（IPF）表現為進行性勞力性呼吸困難及持續性乾咳，聽診時可聞及特徵性的「尼龍搭扣樣」吸氣性囉音。此病以持續性上皮損傷、創傷治療異常和纖維化過度沉積為特徵，導致肺功能下降和氣體交換受損。

特發性肺纖維化（IPF）的病程呈持續進展性，常伴隨急性加重，預後不良，存活期縮短。雖然抗纖維化療法（例如Pirfenidone、尼達尼布）可以延緩疾病進展，但無法逆轉纖維化，肺移植仍是合格的患者唯一的根治性治療方法。

主要亮點

• 特發性肺纖維化是進行性、高度致命的纖維性肺病，治療選擇有限。
• 英國確診病例數預計將從約 38,700 例增加到約 49,100 例（年複合成長率：約 2.4%）。

一項針對醫生和關鍵意見領袖（KOL）的調查得出的結論：

• 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更多見解，從而進一步完善了調查結果。
• 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

• PowerPoint簡報
• MS Excel

主要問題

• 詳細的競爭格局趨勢
• 管道分析
• 符合新興治療方法的患者
• 大公司
• 主要作用機制
• 發布日期等的預測
• 臨床試驗趨勢分析
• 目標患者群
• 試驗終點
• 測試設計
• 受試者招募標準等。
• 未滿足的需求和機遇
• 目前主要治療方法的有效性
• 未滿足需求的關鍵領域
• 估算主要未滿足需求的市場規模
• 目標產品概況
• 屬性和級別
• 醫生開立的處方
• 預期患者佔有率
• 關鍵KOL洞察對領先新興治療方法的見解
• 意識
• 預期用途/處理線
• 對主要未滿足需求的滿意度
• KOL評論

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• PureTech
• AbbVie
• Mediar Therapeutics
• Tvardi Therapeutics, Incorporated
• Contineum Therapeutics
• Calluna Pharma AS
• Haisco Pharmaceutical Group Co., Ltd.
• Boehringer Ingelheim
• Syndax Pharmaceuticals
• Cumberland Pharmaceuticals
• Guangdong Hengrui Pharmaceutical Co., Ltd
• Bristol-Myers Squibb
• Arrowhead Pharmaceuticals
• Rein Therapeutics
• Regend Therapeutics
• Trevi Therapeutics
• Vicore Pharma AB
• Actelion
• Daewoong Pharmaceutical Co. LTD.
• Overseas Pharmaceuticals, Ltd.
• Pliant Therapeutics, Inc.
• Chiesi Farmaceutici SpA
• Bridge Biotherapeutics, Inc.
• GlaxoSmithKline
• HuniLife Biotechnology, Inc.
• Endeavor Biomedicines, Inc.
• siRNAgen Therapeutics Inc.
• Genosco Inc.
• SPARK Biopharma
• Dragonboat Biopharmaceutical Company Limited
• Mannkind Corporation
• Beijing Tide Pharmaceutical Co., Ltd
• Shanghai Synvida Biotechnology Co.,Ltd.
• Guangdong Raynovent Biotech Co., Ltd
• Avalyn Pharma Inc.
• InSilico Medicine Hong Kong Limited
• MediciNova
• GRI Bio Operations, Inc.
• Nerre Therapeutics Ltd.
• Sunshine Lake Pharma Co., Ltd.
• United Therapeutics
• Melius Pharma AB
• Pulmongene Ltd.
• Agomab Spain SL

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要治療方法概述及關鍵意見領袖的見解
• 新興治療方法
• 重點
• 診斷和治療過程/演算法
• 領先的新興治療方法—概述和KOL洞察

第3章 產品屬性分析

• 重點
• 科學屬性
• 商業性屬性
• 產品定位

第4章：初步調查

• 目前治療狀態
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療環境
• 當前挑戰
• 未滿足的需求
• 新興治療方法
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療前景
• 未滿足的需求和關鍵意見領袖的期望

第5章：未滿足的需求和TPP分析

• 新興治療方法的主要未滿足需求和未來成就
• TPP分析與KOL預期

第6章 監理與報銷環境

第7章附錄

Idiopathic Pulmonary Fibrosis (IPF) Emerging Therapy and TPP Insights

Thelansis's "Idiopathic Pulmonary Fibrosis (IPF) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Idiopathic Pulmonary Fibrosis (IPF) Overview

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease of unknown etiology, characterized by irreversible fibrosis of lung parenchyma and a usual interstitial pneumonia (UIP) pattern on high-resolution CT or histopathology. It primarily affects adults over the age of 60 and is one of the most severe forms of idiopathic interstitial pneumonias.

Clinically, IPF presents with progressive exertional dyspnea and persistent dry cough, along with characteristic "Velcro-like" inspiratory crackles on auscultation. The disease is marked by ongoing epithelial injury, aberrant wound healing, and excessive fibrotic deposition, leading to declining lung function and impaired gas exchange.

IPF follows a relentlessly progressive course, often punctuated by acute exacerbations, and is associated with poor prognosis and reduced survival. While antifibrotic therapies (e.g., pirfenidone and nintedanib) can slow disease progression, they do not reverse fibrosis, and lung transplantation remains the only definitive treatment in eligible patients.

Key Highlights

• IPF is a progressive, high-mortality fibrotic lung disease with limited therapeutic options
• UK diagnosed prevalence expected to increase from ~38.7K to ~49.1K (~2.4% CAGR)

Market Overview

• Germany market projected to grow from ~$210M to ~$415M (~7% CAGR)
• Growth driven by antifibrotic therapies and improved diagnosis, with ongoing unmet need for curative treatments

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• PureTech
• AbbVie
• Mediar Therapeutics
• Tvardi Therapeutics, Incorporated
• Contineum Therapeutics
• Calluna Pharma AS
• Haisco Pharmaceutical Group Co., Ltd.
• Boehringer Ingelheim
• Syndax Pharmaceuticals
• Cumberland Pharmaceuticals
• Guangdong Hengrui Pharmaceutical Co., Ltd
• Bristol-Myers Squibb
• Arrowhead Pharmaceuticals
• Rein Therapeutics
• Regend Therapeutics
• Trevi Therapeutics
• Vicore Pharma AB
• Actelion
• Daewoong Pharmaceutical Co. LTD.
• Overseas Pharmaceuticals, Ltd.
• Pliant Therapeutics, Inc.
• Chiesi Farmaceutici S.p.A.
• Bridge Biotherapeutics, Inc.
• GlaxoSmithKline
• HuniLife Biotechnology, Inc.
• Endeavor Biomedicines, Inc.
• siRNAgen Therapeutics Inc.
• Genosco Inc.
• SPARK Biopharma
• Dragonboat Biopharmaceutical Company Limited
• Mannkind Corporation
• Beijing Tide Pharmaceutical Co., Ltd
• Shanghai Synvida Biotechnology Co.,Ltd.
• Guangdong Raynovent Biotech Co., Ltd
• Avalyn Pharma Inc.
• InSilico Medicine Hong Kong Limited
• MediciNova
• GRI Bio Operations, Inc.
• Nerre Therapeutics Ltd.
• Sunshine Lake Pharma Co., Ltd.
• United Therapeutics
• Melius Pharma AB
• Pulmongene Ltd.
• Agomab Spain S.L.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)